Photo: Loren D. Walensky, MD, PhD
Loren D. Walensky, MD, PhD
Year elected: 2010
Current membership category: Active
Dana-Farber Cancer Institute
450 Brookline Avenue, Mayer 664
Boston, MA 02215
United States of America
Phone: 617/632/6307
Facsimile: 617/632-6401

Biographical statement

The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer. To achieve these objectives, we take a multidisciplinary approach that employs synthetic chemistry techniques, structural biology analyses, and biochemical, cellular, and mouse modeling experiments to systematically dissect the pathologic signaling pathways of interest. We have developed and applied new approaches to chemically stabilize natural peptides so that their shape, and therefore their anti-cancer activities can be restored. Optimizing natural peptides in this way provides alternative compounds to study protein interactions and manipulate biological pathways within cells to treat human disease. For example, we have used a chemical strategy, termed “hydrocarbon-stapling,” to synthesize a panel of pro-apoptotic peptides with markedly improved pharmacological properties. We have demonstrated that the stapled peptides retain their natural shape, are resistant to degradation, and can enter and kill leukemia cells by neutralizing their survival proteins. When administered to mice with leukemia, a stapled peptide modeled after the “death domain” of a BCL-2 family protein successfully blocked cancer growth and prolonged the lives of treated animals. In ongoing studies, we broadly apply the new peptide stapling strategy to produce a diversity of cancer biology discovery tools, in order to study and deactivate aberrant apoptotic and transcriptional pathways in a variety of human tumors. Most recently, we used stapled peptides to uncover the elusive “on switch” of a key death-activating protein, unveiling a novel pharmacologic target for cancer drug development. Synthetic approaches such as hydrocarbon-stapling that reinforce native peptide sequence hold promise to provide new avenues for probing protein interactions and modulating biological pathways for therapeutic benefit.

Institutional affiliations

William C. Hahn, MD, PhD is the representative at this institution.

Specialties

Pediatrics